Home » BioDiscovery, Exiqon Ink Deal to Sell miRNA Analysis Package

BioDiscovery, Exiqon Ink Deal to Sell miRNA Analysis Package

May 06, 2010
Premium

BioDiscovery and Exiqon announced this week a deal to package BioDiscovery's array image-analysis software with Exiqon's microRNA arrays.

"The partnership … provides a complete well integrated solution for microRNA array studies, going from array experiment with Exiqon's miRcury LNA microRNA arrays to final results with data analysis and visualization from BioDiscovery software," BioDiscovery President Soheil Shams said in a statement.

Financial terms of the arrangement were not disclosed.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

NIH's Collins on Harassment

In a statement, National Institutes of Health Director Francis Collins says sexual harassment is "morally indefensible" and "unacceptable."

With Eight Arms and Giant Eyes

Octopuses might owe their intelligence to their liberal alterations to their genes, Cosmos reports.

Missing From Trials

Stat News and ProPublica report that African Americans are underrepresented in cancer clinical trials.

This Week in Cell

In Cell this week: genomic analysis of abdominal aortic aneurysm, effect of probiotics on the microbiome, and more.

Nov
05
Featured Webinar

Overcoming Challenges in Solid Tumor Testing with Advanced AI

Sponsored by
Sophia Genetics

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.

What's Popular?

In Gene Silencing/Gene Editing

  1. Horizon Discovery Revenues Double in H1

  2. Thermo Fisher Licenses CRISPR Patents From Broad Institute, ERS Genomics

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2018 GenomeWeb LLC.  All Rights Reserved.